Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 2/2020

01-12-2020 | Central Nervous System Trauma | Study Protocol

Therapeutic effects of supplementation with Curcuminoids in critically ill patients receiving enteral nutrition: a randomized controlled trial protocol

Authors: Hoda Zahedi, Mohammad-Javad Hosseinzadeh-Attar, Amirhossein Sahebkar, Shirin Hasani Ranjbar, Atabak Najafi, Saeed Hosseini, Mostafa Qorbani, Arezoo Ahmadi, Seyed Hossein Ardehali, Hamideh Moravvej, Gholamreza Pourmand, Abdolreza Norouzy, Mahdi Shadnoush

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Login to get access

Abstract

Background

Curcuminoids are dietary polyphenols that can improve health indices through different mechanisms such as anti-inflammatory, antioxidant and immunoregulatory properties. Due to the lack of evidences on the efficacy of curcuminoids in critically ill patients, this study was designed to investigate the effects of short-term curcuminoids supplementation on inflammatory, oxidative stress and adipokine indices as well as nutritional and clinical status in Traumatic Brain Injury (TBI) patients admitted in the Intensive Care Unit (ICU).

Methods

The present trial will be performed in the ICU of Sina and Shohadaye Tajrish hospitals of Tehran, Iran. Sixty-two critically ill patients with TBI will be enrolled based on the eligibility criteria. The patients will be randomly assigned into two groups. For 7 days, they will received either 500 mg curcuminoids in combination with 5 mg piperine or matched placebo. A general questionnaire, consent form as well as NUTRIC, SOFA and APACHEII scoring system and anthropometrics will be assessed at baseline. The inflammatory markers including TNF-α, IL-6, MCP-1 and CRP, oxidative stress indices (GPx and SOD) and adipokines (leptin and adiponetctin) will be measured at baseline and at the end of the study. In addition, dietary intake, concomitant drugs and laboratory tests will be recorded daily.

Discussion

To the best of our knowledge, this is the first clinical trial investigating the effect of curcuminoids supplementation in critically ill patient with TBI. The findings of the present study will provide evidence on the efficacy and safety of curcuminoids in these patients.

Trial registration number

(http://​www.​irct.​ir, identifier: IRCT20180619040151N1), Registration date:18.09.2018.
Literature
1.
go back to reference Plesnila N. The immune system in traumatic brain injury. Curr Opin Pharmacol. 2016;26:110–7.CrossRef Plesnila N. The immune system in traumatic brain injury. Curr Opin Pharmacol. 2016;26:110–7.CrossRef
2.
go back to reference Young LA, Rule GT, Bocchieri RT, Burns JM. Biophysical mechanisms of traumatic brain injuries. Semin Neurol. 2015;35(1):5–11.CrossRef Young LA, Rule GT, Bocchieri RT, Burns JM. Biophysical mechanisms of traumatic brain injuries. Semin Neurol. 2015;35(1):5–11.CrossRef
3.
go back to reference Lozano D, Gonzales-Portillo GS, Acosta S, de la Pena I, Tajiri N, Kaneko Y, et al. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. Neuropsychiatr Dis Treat. 2015;11:97–106.PubMedPubMedCentral Lozano D, Gonzales-Portillo GS, Acosta S, de la Pena I, Tajiri N, Kaneko Y, et al. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. Neuropsychiatr Dis Treat. 2015;11:97–106.PubMedPubMedCentral
4.
go back to reference Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7(8):728–41.CrossRef Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7(8):728–41.CrossRef
5.
go back to reference Finfer SR, Cohen J. Severe traumatic brain injury. Resuscitation. 2001;48(1):77–90.CrossRef Finfer SR, Cohen J. Severe traumatic brain injury. Resuscitation. 2001;48(1):77–90.CrossRef
6.
go back to reference Polinder S, Meerding WJ, Mulder S, Petridou E, van Beeck E. Assessing the burden of injury in six European countries. Bull World Health Organ. 2007;85(1):27–34.CrossRef Polinder S, Meerding WJ, Mulder S, Petridou E, van Beeck E. Assessing the burden of injury in six European countries. Bull World Health Organ. 2007;85(1):27–34.CrossRef
7.
go back to reference Fakharian E, Mohammadzadeh M, Behdadmehr S, Sabri HR, Mirzadeh AS, Mohammadzadeh J. Repetitive traumatic brain injury in patients from Kashan. Iran Trauma Monthly. 2016;21(4):e23869.PubMed Fakharian E, Mohammadzadeh M, Behdadmehr S, Sabri HR, Mirzadeh AS, Mohammadzadeh J. Repetitive traumatic brain injury in patients from Kashan. Iran Trauma Monthly. 2016;21(4):e23869.PubMed
8.
go back to reference Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT. Classification of traumatic brain injury for targeted therapies. J Neurotrauma. 2008;25(7):719–38.CrossRef Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT. Classification of traumatic brain injury for targeted therapies. J Neurotrauma. 2008;25(7):719–38.CrossRef
9.
go back to reference Raj R, Skrifvars M, Bendel S, Selander T, Kivisaari R, Siironen J, et al. Predicting six-month mortality of patients with traumatic brain injury: usefulness of common intensive care severity scores. Crit Care (London, England). 2014;18(2):R60.CrossRef Raj R, Skrifvars M, Bendel S, Selander T, Kivisaari R, Siironen J, et al. Predicting six-month mortality of patients with traumatic brain injury: usefulness of common intensive care severity scores. Crit Care (London, England). 2014;18(2):R60.CrossRef
10.
go back to reference Heyland DK, Dhaliwal R, Jiang X, Day AG. Identifying critically ill patients who benefit the most from nutrition therapy: the development and initial validation of a novel risk assessment tool. Critical care (London, England). 2011;15(6):R268.CrossRef Heyland DK, Dhaliwal R, Jiang X, Day AG. Identifying critically ill patients who benefit the most from nutrition therapy: the development and initial validation of a novel risk assessment tool. Critical care (London, England). 2011;15(6):R268.CrossRef
11.
go back to reference Deguchi A. Curcumin targets in inflammation and cancer. Endocrine, Metab Immune Disord Drug Targets. 2015;15(2):88–96.CrossRef Deguchi A. Curcumin targets in inflammation and cancer. Endocrine, Metab Immune Disord Drug Targets. 2015;15(2):88–96.CrossRef
12.
go back to reference Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin Nutrit (Edinburgh, Scotland). 2015;34(6):1101–8.CrossRef Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin Nutrit (Edinburgh, Scotland). 2015;34(6):1101–8.CrossRef
13.
go back to reference Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of systemic oxidative stress by Curcuminoids in osteoarthritis: results of a randomized controlled trial. J Diet Supplements. 2016;13(2):209–20.CrossRef Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of systemic oxidative stress by Curcuminoids in osteoarthritis: results of a randomized controlled trial. J Diet Supplements. 2016;13(2):209–20.CrossRef
14.
go back to reference Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52(3):167–75.CrossRef Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52(3):167–75.CrossRef
15.
go back to reference Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol. 2014;11(2):123.CrossRef Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol. 2014;11(2):123.CrossRef
16.
go back to reference Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of non-alcoholic fatty liver disease with Curcumin: a randomized placebo-controlled trial. Phytotherapy research : PTR. 2016;30(9):1540–8.CrossRef Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of non-alcoholic fatty liver disease with Curcumin: a randomized placebo-controlled trial. Phytotherapy research : PTR. 2016;30(9):1540–8.CrossRef
17.
go back to reference Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. BioFactors (Oxford, England). 2013;39(1):2–13.CrossRef Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. BioFactors (Oxford, England). 2013;39(1):2–13.CrossRef
18.
go back to reference Corps KN, Roth TL, McGavern DB. Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol. 2015;72(3):355–62.CrossRef Corps KN, Roth TL, McGavern DB. Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol. 2015;72(3):355–62.CrossRef
19.
go back to reference Calabrese V, Bates TE, Mancuso C, Cornelius C, Ventimiglia B, Cambria MT, et al. Curcumin and the cellular stress response in free radical-related diseases. Mol Nutr Food Res. 2008;52(9):1062–73.CrossRef Calabrese V, Bates TE, Mancuso C, Cornelius C, Ventimiglia B, Cambria MT, et al. Curcumin and the cellular stress response in free radical-related diseases. Mol Nutr Food Res. 2008;52(9):1062–73.CrossRef
20.
go back to reference Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013;169(8):1672–92.CrossRef Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013;169(8):1672–92.CrossRef
21.
go back to reference Motterlini R, Foresti R, Bassi R, Green CJ. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med. 2000;28(8):1303–12.CrossRef Motterlini R, Foresti R, Bassi R, Green CJ. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med. 2000;28(8):1303–12.CrossRef
22.
go back to reference Panahi Y, Hosseini MS, Khalili N, Naimi E, Soflaei SS, Majeed M, et al. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition (Burbank, Los Angeles County, Calif). 2016;32(10):1116–22.CrossRef Panahi Y, Hosseini MS, Khalili N, Naimi E, Soflaei SS, Majeed M, et al. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition (Burbank, Los Angeles County, Calif). 2016;32(10):1116–22.CrossRef
23.
go back to reference Rahimnia AR, Panahi Y, Alishiri G, Sharafi M, Sahebkar A. Impact of supplementation with Curcuminoids on systemic inflammation in patients with knee osteoarthritis: findings from a randomized double-blind placebo-controlled trial. Drug Res. 2015;65(10):521–5. Rahimnia AR, Panahi Y, Alishiri G, Sharafi M, Sahebkar A. Impact of supplementation with Curcuminoids on systemic inflammation in patients with knee osteoarthritis: findings from a randomized double-blind placebo-controlled trial. Drug Res. 2015;65(10):521–5.
24.
go back to reference Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules (Basel, Switzerland). 2011;16(6):4567–98.CrossRef Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules (Basel, Switzerland). 2011;16(6):4567–98.CrossRef
25.
go back to reference Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res. 2008;52(9):1010–30.CrossRef Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res. 2008;52(9):1010–30.CrossRef
Metadata
Title
Therapeutic effects of supplementation with Curcuminoids in critically ill patients receiving enteral nutrition: a randomized controlled trial protocol
Authors
Hoda Zahedi
Mohammad-Javad Hosseinzadeh-Attar
Amirhossein Sahebkar
Shirin Hasani Ranjbar
Atabak Najafi
Saeed Hosseini
Mostafa Qorbani
Arezoo Ahmadi
Seyed Hossein Ardehali
Hamideh Moravvej
Gholamreza Pourmand
Abdolreza Norouzy
Mahdi Shadnoush
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-019-00451-w

Other articles of this Issue 2/2020

Journal of Diabetes & Metabolic Disorders 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.